ReviewWorld journal of urology2021
Follow-up in non-muscle invasive bladder cancer: facts and future.
Review in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study.Translational andrology and urology · 2026Article
- Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer.International journal of molecular sciences · 2026Article
- High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience.Frontiers in oncology · 2026Article
- Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer.Frontiers in oncology · 2025Review
- Review
- Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer.Asian journal of urology · 2024Article
- Association between tobacco exposure and bladder cancer recurrence: A systematic review and meta-analysis.World journal of methodology · 2024Article
- The Evolution of Polyclonal Antibody from Specific Epitope 47kDA for Detection of Bladder Cancer.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Study of Liquid-Based Cytology Using Next-Generation Sequencing as a Liquid Biopsy Application in Patients with Advanced Oncological Disease.Biomedicines · 2023Article
- Adherence to guidelines in the follow-up of non-muscle-invasive bladder cancer among urology trainers and trainees in Jordan: a cross-sectional study.Annals of medicine and surgery (2012) · 2023Article
- A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.Frontiers in immunology · 2023Article
- Loss of Lactate/Proton Monocarboxylate Transporter 4 Induces Ferroptosis via the AMPK/ACC Pathway and Inhibition of Autophagy on Human Bladder Cancer 5637 Cell Line.Journal of oncology · 2023Article
- Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer.Pharmaceutics · 2022Review
- The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Usefulness of the Urine Methylation Test (Bladder EpiCheckJournal of clinical medicine · 2022Article
- [Follow-up in superficial and metastatic bladder cancer].Der Urologe. Ausg. A · 2022Review
- Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results.World journal of urology · 2022Article
- The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with non-muscle invasive bladder cancer (NMIBC) have high recurrence and progression rates in spite of tumor resection and adjuvant instillation therapy. To detect recurrences and progression, these patients remain under frequent follow-up. Follow-up, however, is not well defined. Frequency and duration of follow recommendations are based on low levels of evidence, which is illustrated by clear differences in these recommendations per guideline, even when specified per risk group. Additionally, follow-up is recommended with cystoscopy and cytology in selected patients, which both have clear limitations. Fact is that follow-up in NMIBC is too frequent, with low levels of evidence and suboptimal tools, and it is patient unfriendly and costly. Improved cystoscopy techniques are unproven or impractical in the outpatient follow-up setting. Urinary markers have been around for decades, but never widely used in clinical practice. New (epi)genetic markers, however, could play a significant role in future follow-up of NMIBC. They have been shown to have very high negative predictive values for recurrences in follow-up of NMIBC, especially high-grade recurrences. Several studies suggested that these markers could be used to adapt follow-up cystoscopy frequency. What still needs study and confirmation is the cost-effectiveness of the use of these markers, which is highly dependent on health care costs per country and marker price. In all, however, implementation of these new urinary markers after confirmation of current results might significantly reduce patient burden and health care costs in the near future without reducing quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.